Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Angulo JC, Álvarez-Ossorio JL, Domínguez-Escrig JL, Moyano JL, Sousa A, Fernández JM, Gómez-Veiga F, Unda M, Carballido J, Carrero V, Fernandez-Aparicio T, García de Jalón Á, Solsona E, Inman B, Palou J. Angulo JC, et al. Among authors: unda m. Eur Urol Oncol. 2023 Feb;6(1):58-66. doi: 10.1016/j.euo.2022.10.008. Epub 2022 Nov 23. Eur Urol Oncol. 2023. PMID: 36435738 Clinical Trial.
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, Alonso JM, Astobieta A, Unda M, Martinez-Piñeiro L, Rabadan M, Ojea A, Rodriguez-Molina J, Beardo P, Muntañola P, Gomez M, Montesinos M, Martinez Piñeiro JA; Members of Club Urológico Español de Tratamiento Oncológico. Solsona E, et al. Among authors: unda m. Eur Urol. 2015 Mar;67(3):508-16. doi: 10.1016/j.eururo.2014.09.026. Epub 2014 Oct 6. Eur Urol. 2015. PMID: 25301758 Clinical Trial.
Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L, Portillo JA, Fernández JM, Zabala JA, Cadierno I, Moyano JL, Solsona E, Unda M, Beardo P, Rodríguez-Molina J, Chantada V, Palou J, Muntañola P, Alonso Dorrego JM, Pérez-Garcia FJ, Silva JM, Chesa N, Montesinos M, Ojea A, Madero R, Martínez-Piñeiro JA. Martínez-Piñeiro L, et al. Among authors: unda m. Eur Urol. 2015 Aug;68(2):256-62. doi: 10.1016/j.eururo.2015.02.040. Epub 2015 Mar 18. Eur Urol. 2015. PMID: 25794457 Clinical Trial.
The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Ojea A, Portillo J, Montesinos M, Gonzalez M, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA; Club Urológico Español de Tratamiento Oncológico. Fernandez-Gomez J, et al. Among authors: unda m. Eur Urol. 2011 Sep;60(3):423-30. doi: 10.1016/j.eururo.2011.05.033. Epub 2011 May 25. Eur Urol. 2011. PMID: 21621906
Influence of the true number of Bacillus Calmette-Guérin instillations on the prognosis of non-muscle invasive bladder tumors.
Portillo JA, Madero R, Solsona E, Fernandez JM, Martínez-Piñeiro L, Palou J, Montesino M, Martínez-Piñeiro JA, Unda M; Miembros del grupo CUETO (Club Urológico Español de Tratamientos Oncológicos). Portillo JA, et al. Among authors: unda m. Actas Urol Esp. 2014 Jun;38(5):280-4. doi: 10.1016/j.acuro.2013.10.010. Epub 2014 Feb 14. Actas Urol Esp. 2014. PMID: 24529538 English, Spanish.
Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
Palou-Redorta J, Solsona E, Angulo J, Fernández JM, Madero R, Unda M, Martínez-Piñeiro JA, Portillo J, Chantada V, Moyano JL. Palou-Redorta J, et al. Among authors: unda m. Actas Urol Esp. 2016 Jul-Aug;40(6):370-7. doi: 10.1016/j.acuro.2015.12.009. Epub 2016 Feb 24. Actas Urol Esp. 2016. PMID: 26922518 English, Spanish.
Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
Fernandez-Gomez J, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Isorna S, Rabadan M, Astobieta A, Montesinos M, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA; Club Urológico Español de Tratamiento Oncológico (CUETO). Fernandez-Gomez J, et al. Among authors: unda m. Eur Urol. 2008 May;53(5):992-1001. doi: 10.1016/j.eururo.2007.10.006. Epub 2007 Oct 15. Eur Urol. 2008. PMID: 17950987
[Consensus on castration-resistant prostate cancer management in Spain.].
Alcaraz A, Martínez-Piñeiro L, Rodríguez A, Rubio J, Borque Á, Burgos J, Carballido J, Cózar JM, Crespo I, Esquena S, Gómez-Veiga F, López D, Miñana B, Morote J, Ribal MJ, Solsona E, Suárez JF, Unda M. Alcaraz A, et al. Among authors: unda m. Arch Esp Urol. 2017 Nov;70(9):777-791. Arch Esp Urol. 2017. PMID: 29099380 Free article. Spanish.
Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA. Fernandez-Gomez J, et al. Among authors: unda m. J Urol. 2009 Nov;182(5):2195-203. doi: 10.1016/j.juro.2009.07.016. Epub 2009 Sep 16. J Urol. 2009. PMID: 19758621
62 results